Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL143594 | 0.99 | SLC6A4 (0.73) | SLC6A4 | |
| SCHEMBL339642 | 0.90 | SLC6A4 (0.75) | SLC6A4 | |
| SCHEMBL2009409 | 0.90 | SLC6A4 (0.75) | SLC6A4 | |
| SCHEMBL2006721 | 0.90 | SLC6A4 (0.75) | SLC6A4 | |
| SCHEMBL7688733 | 0.89 | SLC6A4 (0.73) | SLC6A4 | |
| SCHEMBL2872832 | 0.87 | SLC6A4 (0.68) | SLC6A4 | |
| SCHEMBL15152288 | 0.86 | SLC6A4 (1.00) | SLC6A4 | |
| SCHEMBL15152289 | 0.86 | SLC6A4 (1.00) | SLC6A4 | |
| SCHEMBL15152141 | 0.86 | SLC6A4 (1.00) | SLC6A4 | |
| Hydrochloric Acid SCHEMBL15152150 | 0.85 | SLC6A4 (0.98) | SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0474580-B1 | Use of 1-[3-(dimethylamino)propyl]-1-phenylphthalenes for the treatment of cerebrovascular disorders | LUNDBECK & CO AS H (DK) | 1994-09-28 | — | — | EP | claimed |
| US-5296507-A | Treatment of cerbrovascular disorders | H.LUNDBECK A/S (DK) | 1994-03-22 | — | — | US | claimed |
| EP-0474580-A2 | Use of 1-[3-(dimethylamino)propyl]-1-phenylphthalenes for the treatment of cerebrovascular disorders | H. LUNDBECK A/S (DK) | 1992-03-11 | — | — | EP | claimed |
| JP-4244024-A | — | — | None | — | — | JP | disclosed |
| WO-2013110313-A1 | SELECTIVE ALLOSTERIC MODULATORS OF THE SEROTONIN TRANSPORTER | H. LUNDBECK A/S (DK) | 2013-08-01 | — | — | WO | disclosed |
| US-8242159-B2 | 1,3-dihydro-5-isobenzofurancarbonitrile derivatives and pharmaceutical composition thereof for the treatment of premature ejaculation | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2012-08-14 | — | — | US | disclosed |
| CN-101910146-A | Novel 1,3-dihydro-5-isobenzofurancarbonitrile derivatives and pharmaceutical composition thereof for the treatment of premature ejaculation | DONG A PHARM CO LTD | 2010-12-08 | — | — | CN | disclosed |
| US-20100240725-A1 | NOVEL 1,3-DIHYDRO-5-ISOBENZOFURANCARBONITRILE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF PREMATURE EJACULATION | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2010-09-23 | — | — | US | disclosed |
| WO-2008059514-A2 | PROCESS FOR PREPARING ESCITALOPRAM | CADILA HEALTHCARE LIMITED (IN) | 2008-05-22 | — | — | WO | disclosed |
| EP-1502907-A1 | A process for the preparation of (2-hydroxymethyl-phenyl)-phenyl-methanol derivatives | Synteco S.p.A. (IT) | 2005-02-02 | — | — | EP | disclosed |
| EP-0474580-B1 | Use of 1-[3-(dimethylamino)propyl]-1-phenylphthalenes for the treatment of cerebrovascular disorders | LUNDBECK & CO AS H (DK) | 1994-09-28 | — | — | EP | disclosed |
| US-5296507-A | Treatment of cerbrovascular disorders | H.LUNDBECK A/S (DK) | 1994-03-22 | — | — | US | disclosed |
| US-5296507-A | Treatment of cerbrovascular disorders | H.LUNDBECK A/S (DK) | 1994-03-22 | — | — | US | disclosed |
| JP-H04244024-A | PREVENTING AND TREATING AGENT FOR DEMENSIA AND CEREBROVASCULAR DISORDER AND INHIBITOR OF BLOOD PLATELET AGGREGATION | ZERIA PHARMACEUT CO LTD | 1992-09-01 | — | — | JP | disclosed |
| EP-0474580-A2 | Use of 1-[3-(dimethylamino)propyl]-1-phenylphthalenes for the treatment of cerebrovascular disorders | H. LUNDBECK A/S (DK) | 1992-03-11 | — | — | EP | disclosed |
| EP-0474580-A2 | Use of 1-[3-(dimethylamino)propyl]-1-phenylphthalenes for the treatment of cerebrovascular disorders | H. LUNDBECK A/S (DK) | 1992-03-11 | — | — | EP | disclosed |
| EP-0171943-B1 | NOVEL INTERMEDIATE AND METHOD FOR ITS PREPARATION | H. LUNDBECK A/S (DK) | 1988-11-17 | — | — | EP | disclosed |
| US-4650884-A | 4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile (racemic citalopram diol) as intermediate to citalopram | H. LUNDBECK A/S (DK) | 1987-03-17 | — | — | US | disclosed |
| EP-0171943-A1 | Novel intermediate and method for its preparation | H. LUNDBECK A/S (DK) | 1986-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240725-A1 | NOVEL 1,3-DIHYDRO-5-ISOBENZOFURANCARBONITRILE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF PREMATURE EJACULATION | SLC18A2, SLC18A1, SLC6A4 | SLC6A4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.